Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription - Summary - MDSpire
Advertisement
Reassessing Empirical Use of Vancomycin in Pediatric Patients in Areas with Low MRSA Incidence: A Study of Necessity and Overprescription
To determine the incidence of pediatric patients empirically treated with vancomycin who truly required it as definitive therapy and to identify specific clinical and demographic factors associated with such necessity.
Key Findings:
Only 8.3% to 9.6% of S. aureus isolates in Thailand were MRSA during 2020-2022, indicating low justification for empirical vancomycin use based on MRSA concerns, which necessitates a reevaluation of prescribing practices.
A significant proportion of empirical vancomycin prescriptions were found to be inappropriate in various studies, with 65.7% in Brazil and 62% in the U.S. not adhering to guidelines.
The study aims to provide guidance for more appropriate prescribing of empirical vancomycin to reduce resistance and side effects.
Interpretation:
The low incidence of MRSA in Thailand suggests that empirical vancomycin use may often be unwarranted, highlighting the need for more judicious prescribing practices to avoid unnecessary treatment.
Limitations:
The study is retrospective and may be subject to biases inherent in such designs, including confounding factors.
Data was collected from a single hospital, which may limit generalizability.
Conclusion:
Improving the appropriateness of empirical vancomycin use in pediatric patients could help mitigate the risk of developing vancomycin-resistant bacteria and reduce adverse effects.
A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.
